Abpro Holdings, Inc. (ABP)
NASDAQ: ABP · Real-Time Price · USD
1.930
-0.020 (-1.03%)
At close: Jan 30, 2026, 4:00 PM EST
1.900
-0.030 (-1.55%)
After-hours: Jan 30, 2026, 4:57 PM EST
Abpro Holdings Revenue
In the year 2024, Abpro Holdings had annual revenue of $183.00K with 50.00% growth.
Revenue (ttm)
$183.00K
Revenue Growth
+50.00%
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
15
Market Cap
5.24M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 183.00K | 61.00K | 50.00% |
| Dec 31, 2023 | 122.00K | -1.91M | -93.99% |
| Dec 31, 2022 | 2.03M | 1.55M | 322.71% |
| Dec 31, 2021 | 480.00K | -1.72M | -78.19% |
| Dec 31, 2017 | 2.20M | 516.00K | 30.62% |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2010 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Moolec Science | 7.83M |
| GeoVax Labs | 3.35M |
| Xenetic Biosciences | 2.86M |
| Cyclerion Therapeutics | 2.86M |
| Can-Fite BioPharma | 560.00K |
| Bio Green Med Solution | 81.00K |
ABP News
- 16 days ago - Abpro's Lead Program ABP-102 Featured in Celltrion Presentation at the 44th Annual J.P. Morgan Healthcare Conference - GlobeNewsWire
- 25 days ago - Abpro and Celltrion, Inc. Announce U.S. FDA IND Clearance for Lead Multispecific Antibody Cancer Candidate ABP-102 / CT-P72 - GlobeNewsWire
- 6 weeks ago - Abpro Holdings Announces Submission of an IND Application to Initiate a Phase 1 Clinical Trial of T cell engager ABP-102/CT-P72 for HER2-positive Cancers - GlobeNewsWire
- 7 weeks ago - Abpro Granted Nasdaq Listing Extension to Pursue Compliance and Strategic Objectives - GlobeNewsWire
- 3 months ago - Abpro and Celltrion to Present Preclinical Data for CT-P72/ABP-102 at SITC 2025, Highlighting a Next-Generation HER2×CD3 T-Cell Engager - GlobeNewsWire
- 3 months ago - Abpro Announces 1-for-30 Reverse Stock Split Effective November 3, 2025 - GlobeNewsWire
- 9 months ago - Abpro and Celltrion Unveil Preclinical Data for ABP-102/CT-P72 at AACR 2025, Showcasing Potential Best-in-Class HER2 x CD3 T-Cell Engager - GlobeNewsWire
- 11 months ago - Abpro Announces Oral Presentation of First Preclinical Data for ABP-102/CT-P72, a Tetravalent Bispecific HER2 x CD3 T-Cell Engager, at AACR Annual Meeting 2025 - GlobeNewsWire